The crucial trials Medtronic has had to pause

Covid-19 could mean Medtronic loses out to Abbott, its rival in the mitral valve space.

Corporate strategy

Geoff Martha has taken over as chief executive of Medtronic in less than ideal circumstances. The world’s largest medtech has been hit hard by patients delaying elective surgical procedures so as to stay out of hospital while the Covid-19 pandemic rages on. Last week Medtronic said its weekly US sales for the past few weeks had declined around 60% year over year.

This is bad enough. But the group also said it would pause enrolment into its clinical trials currently recruiting patients, “to allow hospital clinical resources to focus on fighting Covid-19”. This could have a longer-term effect, delaying the launch of some of its important new products, most notably Intrepid, its transcatheter mitral valve. 

The pivotal US trial of Intrepid is – or was – still in its recruitment phase. The Apollo study aimed to sign up 1,600 patients with moderate or severe symptomatic mitral regurgitation and compare the minimally invasive valve with surgical valve implantation. Results were expected in the third quarter of 2021. 

This is now in doubt, which is a concern since Abbott Laboratories is hot on Medtronic’s heels. Abbott’s US pivotal of its own mitral valve, Tendyne, is scheduled to conclude in spring 2022, and the group has said nothing about halting recruitment into this or any other study. If Abbott can keep its trial on track, Medtronic’s first mover advantage could shrink or disappear entirely. 

The mitral race: Medtronic and Abbott's US pivotal studies
Company Device Trial name N PCD Trial ID
Abbott Laboratories Tendyne Summit 958 Jun 2022 NCT03433274
Medtronic Intrepid Apollo 1600 Oct 2021 NCT03242642
PCD = primary completion date. Source: Clinicaltrials.gov & company communications.

Another transcatheter valve trial will also be affected by the trial halt. A small study of the Harmony pulmonary valve had been expected to read out in the coming months but according to clinicaltrials.gov is still recruiting patients. This could slow Medtronic’s plans to add a second pulmonary valve to its offering – its Melody device has been on sale in Europe since 2006 and in the US since 2010. 

Lastly, a trial investigating the application of Medtronic’s Visualase laser ablation system to temporal lobe epilepsy could be delayed beyond 2022. The device is used under MRI guidance, and is approved as a surgical device for many different applications; this trial specifically examines its use in patients with drug-resistant epilepsy, a significant unmet need.

Of these trials, Apollo is by far the most important to Medtronic’s ambitions. The table below shows EvaluateMedTech’s consensus sales forecasts for the top five medtechs in 2026, and while Medtronic is still forecast to be at the top Abbott is set to climb the rankings. If Apollo is halted for six months or so and Summit continues as scheduled, the valves could be launched in the US at roughly the same time, giving Abbott a better chance than it might otherwise have had.

Top 5 medtech companies in 2026
  Total medtech sales 2019 ($bn) Total medtech sales 2026e ($bn) CAGR Market share 2019 Market share 2026e
Medtronic 30.8 42.4 +5% 6.8% 5.9%
Johnson & Johnson 26.0 33.1 +4% 5.7% 4.6%
Abbott Laboratories 19.9 30.7 +6% 4.4% 4.3%
Stryker 14.9 22.1 +6% 3.3% 3.1%
Siemens Healthineers 16.3 22.1 +4% 3.6% 3.1%
Source: EvaluateMedTech.

Medtronic will report its full-year results for fiscal 2020 next month, and has already cautioned that it expects further pressure from the pandemic, stating that its results will reflect an additional month of impact compared with many other companies that operate on a calendar-based fiscal year. 

It also set out where it expects to see the most dramatic effects. The products used in more urgent procedures such as pacemakers and its Solitaire device, used to treat ischaemic stroke, are likely to continue selling; its cryoablation catheters, used in atrial fibrillation, and attempts to move diabetes patients onto its insulin pumps, might be less resilient. 

Medtronic’s therapies – urgent vs elective
More urgent Moderately elective More elective
Cardiac and vascular 
Pacing Implanted defibrillators Atrial fibrillation
Aortic TAVR/structural heart Endovenous
Coronary Peripheral Diagnostics
Cardiac surgery    
Minimally invasive therapies 
Surgery: appendectomy, bowel obstruction, trauma Surgery: CABG, oncology Surgery: bariatric, hysterectomy, hernia
Respiratory and patient monitoring   Gastrointestinal
Renal Care    
Restorative therapies 
Spine trauma Brain modulation Other spine
Neurovascular: ischaemic stroke Neurovascular: haemorrhagic stroke  Pain therapies
    Pelvic health
    Ear, nose and throat
Diabetes 
Diabetes supplies   New insulin pump starts
TAVR = transcatheter aortic valve replacement. CABG = coronary artery bypass graft.Source: adapted from Medtronic release.

Share This Article